SciSparc Granted Another Patent, Strengthening its Core Technology in Canada
March 18 2024 - 7:29AM
SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty
clinical-stage pharmaceutical company focusing on the development
of therapies to treat disorders and rare diseases of the central
nervous system, today announced that it has been granted a patent
for its core-technology, the combination of cannabinoids and
n-acylethanolamines, by the Canadian Intellectual Property Office
(the “Patent”). The Patent aligns seamlessly with the Company's
proprietary technology and is designed to enhance the safety of
cannabinoids by using low dosages of active components while
maintaining their therapeutic benefits.
This patent grant adds to the patent portfolio of the Company,
thereby supporting the innovation of SciSparc’s technologies.
Oz Adler, CEO of SciSparc, commented, “With this patent, we
continue to strengthen our global intellectual property rights.
SciSparc is a unique company in the cannabis space. We believe we
are building value for our investors, as the Company continues to
develop technologies for the treatment of central nervous system
disorders."
The Patent covers the compositions and methods for potentiating
therapeutic effects and/or reducing the side-effects of selected
cannabinoids initially discovered in the cannabis plant. The Patent
was granted on account of the unique composition of cannabinoids
and n-acylethanolamines and the methods for their use in preventing
and treating a variety of cannabinoid-treated conditions.
About SciSparc Ltd. (Nasdaq:
SPRC):
SciSparc Ltd. is a specialty clinical-stage pharmaceutical
company led by an experienced team of senior executives and
scientists. SciSparc’s focus is on creating and enhancing a
portfolio of technologies and assets based on cannabinoid
pharmaceuticals. With this focus, the Company is currently engaged
in the following drug development programs based on THC and/or
non-psychoactive CBD: SCI-110 for the treatment of Tourette
Syndrome, for the treatment of Alzheimer's disease and agitation;
SCI-160 for the treatment of pain; and SCI- 210 for the treatment
of ASD and status epilepticus. The Company also owns a controlling
interest in a subsidiary whose business focuses on the sale of hemp
seeds oil-based products on the Amazon.com Marketplace.
Forward-Looking Statements:
This press release contains forward-looking statements within
the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995 and other Federal
securities laws. For example, SciSparc is using forward-looking
statements when it discusses: the Company’s continued effort to
strengthen its global intellectual property rights; its belief that
its is building value for its inestors; and that it continues to
develop technologies for the treatment of central nervous system
disorders. Because such statements deal with future events and are
based on SciSparc's current expectations, they are subject to
various risks and uncertainties and actual results, performance or
achievements of SciSparc could differ materially from those
described in or implied by the statements in this press release.
The forward-looking statements contained or implied in this press
release are subject to other risks and uncertainties, including
those discussed under the heading "Risk Factors" in SciSparc's
Annual Report on Form 20-F filed with the SEC on May 1, 2023,
and in subsequent filings with the U.S. Securities and Exchange
Commission. Except as otherwise required by law, SciSparc disclaims
any intention or obligation to update or revise any forward-looking
statements, which speak only as of the date they were made, whether
as a result of new information, future events or circumstances or
otherwise.
Investor Contact:IR@scisparc.comTel: +972-3-6167055
SciSparc (NASDAQ:SPRC)
Historical Stock Chart
From Mar 2024 to Apr 2024
SciSparc (NASDAQ:SPRC)
Historical Stock Chart
From Apr 2023 to Apr 2024